v3.26.1
Significant Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2026
Apr. 01, 2026
Sep. 30, 2025
Jun. 30, 2024
Nov. 30, 2022
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration revenue           $ (257,000) $ 8,513,000 $ 991,000 $ 12,640,000  
Cumulative catch-up adjustment to collaboration revenue $ (2,600,000)                  
Recognized revenue 2,300,000                  
Accounts receivable           0   0   $ 305,000
Remaining performance obligation as revenue $ 12,400,000                  
Acuitas License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
License fee     $ 3,000,000              
Affini-T Therapeutics, Inc. | Development, Option and License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaborations revenue             300,000   400,000  
Accounts receivable           0   0   0
Remaining performance obligation as revenue                   0
Ionis                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration revenue           (300,000) 8,200,000 1,000,000 12,200,000  
Accounts receivable           0   0   300,000
Deferred revenue           0 $ 7,500,000 300,000 $ 9,900,000  
Deferred revenue           11,200,000   11,200,000   $ 11,700,000
Proceeds from manufactured components           2,500,000   2,500,000    
Additional exploratory cost reimbursements amount   $ 0                
Ionis | Collaboration and License Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Remaining performance obligation as revenue           12,700,000   12,700,000    
Reimbursable expenses received           6,500,000   6,500,000    
Upfront payment received         $ 80,000,000          
Reimbursement for research costs         10,000,000          
Estimated transaction price         90,000,000          
Collaboration agreement upfront payment received         $ 80,000,000          
Percentage added to cost of goods that represents price of manufactured components         15.00%          
Reimbursable internal costs and out-of-pocket costs payable in quarterly installments         $ 500,000          
Increase in variable consideration       $ 3,400,000            
Ionis | Collaboration and License Agreement | Wave 2 Target                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential future target selection fee         15,000,000          
Ionis | Collaboration and License Agreement | Selected Target                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Potential future target selection fee         30,000,000          
Ionis | Collaboration and License Agreement | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Reimbursable internal costs and out-of-pocket costs         10,000,000          
Future development milestone payments to be received           29,000,000   29,000,000    
Future regulatory milestone payments to be received           60,000,000   60,000,000    
Fututre sales-based milestones to be received           $ 250,000,000   $ 250,000,000    
Ionis | Co-Develop and Co-Commercialize Licensed Products                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Exercise fee description               The Co-Co Option exercise fee will equal 50% of Ionis’ internal costs and out-of-pocket costs incurred in the conduct of the drug discovery activities prior to the exercise of the Co-Co Option and be reduced by 50% of the Company’s corresponding costs incurred.    
Cost - share percentage description               The Company may elect to reduce its cost-share percentage anywhere between 50% and 25% on a go-forward basis, provided the Company will continue to bear 50% of the costs of any clinical trials ongoing at the time of the election through the completion of the clinical trials.    
Ionis | Discovery Program                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Revenue         80,000,000          
Ionis | Exploratory Program                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Revenue         $ 10,000,000